30Mar
30Mar
Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine
San Francisco, CA., March 30, 2026 — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $15 million grant to support the expanded clinical development of ISP-001, its lead investigational therapy for the treatment of mucopolysaccharidosis type I (MPS I), a rare and life-threatening lysosomal storage disorder. “There is no cure for MPS I, and there is a significant unmet need for therapies that...
27Mar
GelMEDIX, Catalent Partner to Advance iPSC-Derived Cell Therapies
GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent Inc., a global contract development and manufacturing organization (CDMO), have partnered to utilize Catalent’s GMP-induced pluripotent stem cells (iPSC) and cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases. Read More>>
02Mar
Akston Chooses Louisiana for Major Life Sciences Manufacturing Expansion
SHREVEPORT, La. — Akston, a biotechnology company focused on animal health, has opened a new manufacturing facility as part of a $7 million investment in Caddo Parish to expand its U.S. manufacturing capabilities and strengthen Louisiana’s life sciences sector. Read More>>
17Feb
GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership
— Proceeds to support advancement of lead cell therapy program for Geographic Atrophy and next-generation hydrogel regenerative therapy platform — — Partnership with global pharmaceutical company will leverage GelMEDIX regenerative medicine technology to develop stem cell-derived cell therapies — CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- GelMEDIX, Inc., a biotechnology company developing regenerative therapies to restore vision, announced today the completion of a $13 million seed financing led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor...
26Jan